ADC’s loncastuximab data could clear path for BLA, IPO filing

Months after scuttling a planned listing, ADC Therapeutics intends to refile for an IPO as it prepares to submit a BLA in 3Q19 seeking accelerated approval for its antibody-drug conjugate to treat DLBCL in a third-line setting.

The company said Thursday that loncastuximab tesirine (ADCT-402) led to an overall response rate (ORR) of 45.5%, including a 20% complete response rate, among 145 patients in a pivotal Phase II trial to treat relapsed or refractory diffuse large B cell lymphoma. CEO Chris Martin told BioCentury that based on the company’s conversations with FDA, ADC Therapeutics S.A. hoped to show at least a 40% ORR in the trial...